Literature DB >> 10646119

Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover.

N Z Angel1, N Walsh, M R Forwood, M C Ostrowski, A I Cassady, D A Hume.   

Abstract

Tartrate-resistant acid phosphatase (TRAP) is a secreted product of osteoclasts and a lysosomal hydrolase of some tissue macrophages. To determine whether TRAP expression is rate-limiting in bone resorption, we overexpressed TRAP in transgenic mice by introducing additional copies of the TRAP gene that contained the SV40 enhancer. In multiple independent mouse lines, the transgene gave a copy number-dependent increase in TRAP mRNA levels and TRAP activity in osteoclasts, macrophages, serum, and other sites of normal low-level expression (notably, liver parenchymal cells, kidney mesangial cells, and pancreatic secretory acinar cells). Transgenic mice had decreased trabecular bone consistent with mild osteoporosis. Measurements of the bone formation rate suggest that the animals compensate for the increased resorption by increasing bone synthesis, which partly ameliorates the phenotype. These mice provide evidence that inclusion of an irrelevant enhancer does not necessarily override a tissue-specific promoter.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646119     DOI: 10.1359/jbmr.2000.15.1.103

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  33 in total

1.  Polarization and secretion of cathepsin K precede tartrate-resistant acid phosphatase secretion to the ruffled border area during the activation of matrix-resorbing clasts.

Authors:  Karin Hollberg; Joakim Nordahl; Kjell Hultenby; Silwa Mengarelli-Widholm; Göran Andersson; Finn P Reinholt
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

2.  Mechanisms of osteoclast-dependent bone formation.

Authors:  Anna Teti
Journal:  Bonekey Rep       Date:  2013-12-04

3.  Effects of Bisphosphonate Administration on Cleft Bone Graft in a Rat Model.

Authors:  Nicole Cheng; Juyoung Park; Jeffrey Olson; Taewoo Kwon; Deborah Lee; Rachel Lim; Sandy Ha; Reuben Kim; Xinli Zhang; Kang Ting; Sotirios Tetradis; Christine Hong
Journal:  Cleft Palate Craniofac J       Date:  2017-01-17

4.  Direct observation of multiple protonation states in recombinant human purple acid phosphatase.

Authors:  Enrico G Funhoff; Thyra E de Jongh; Bruce A Averill
Journal:  J Biol Inorg Chem       Date:  2005-09-23       Impact factor: 3.358

5.  Osteoclast-Associated Receptor (OSCAR) Distribution in the Synovial Tissues of Patients with Active RA and TNF-α and RANKL Regulation of Expression by Osteoclasts In Vitro.

Authors:  Anak A S S K Dharmapatni; Kent Algate; Roxanne Coleman; Michelle Lorimer; Melissa D Cantley; Malcolm D Smith; Mihir D Wechalekar; Tania N Crotti
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

6.  Disruption of the transcription factor RBP-J results in osteopenia attributable to attenuated osteoclast differentiation.

Authors:  Jing Ma; Ya-Li Liu; Yi-Yang Hu; Ya-Ning Wei; Xing-Cheng Zhao; Guang-Ying Dong; Hong-Yan Qin; Yin Ding; Hua Han
Journal:  Mol Biol Rep       Date:  2012-12-07       Impact factor: 2.316

7.  Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha.

Authors:  Kazunori Hamamura; Nancy Tanjung; Hiroki Yokota
Journal:  J Bone Miner Metab       Date:  2013-03-28       Impact factor: 2.626

Review 8.  Interaction of staphylococci with bone.

Authors:  John A Wright; Sean P Nair
Journal:  Int J Med Microbiol       Date:  2009-11-03       Impact factor: 3.473

9.  Defective co-activator recruitment in osteoclasts from microphthalmia-oak ridge mutant mice.

Authors:  Sudarshana M Sharma; Said Sif; Michael C Ostrowski; Uma Sankar
Journal:  J Cell Physiol       Date:  2009-07       Impact factor: 6.384

Review 10.  Osteoclasts: more than 'bone eaters'.

Authors:  Julia F Charles; Antonios O Aliprantis
Journal:  Trends Mol Med       Date:  2014-07-06       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.